Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03508700 · ClinicalTrials.gov registry record · Phase 3
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
A Phase 3 study of PTSD, sponsored by Tonix Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 93
- Enrollment target
- 16
- Study locations
NCT03508700 is a Phase 3 study of PTSD that has completed, run by Tonix Pharmaceuticals. The registered enrollment target is 93 participants, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (69% lower). The trial reports 16 study locations across 11 states.
The verdict
NCT03508700, a Phase 3 study of PTSD, has completed, sponsored by Tonix Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 93 participants
- Enrollment target
- 16
- Study locations
Study Summary
Evaluate the long-term safety of TNX-102 SL 5.6 mg taken daily at bedtime over an additional 40 weeks in patients with PTSD who have participated in a double-blind lead-in study and completed an initial 12-week open-label extension study (TNX-CY-P303).
Conditions Studied
Interventions
- DRUG TNX-102 SL 5.6 mg
Study Locations (16)
California
- Beverly Hills - Beverly Hills
- Oceanside - Oceanside
- Orange - Orange
- Temecula - Temecula
New York
- Cedarhurst - Cedarhurst
- New York - New York
Ohio
- Canton - Canton
- Cincinnati - Cincinnati
Arkansas
- Little Rock - Little Rock
Colorado
- Colorado Springs - Colorado Springs
Connecticut
- Norwich - Norwich
Florida
- Tampa - Tampa
Georgia
- Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2018-04-19 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03508700
The ClinicalTrials.gov registry entry for NCT03508700 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (69% lower). The listed sponsor is Tonix Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 1 intervention - of which TNX-102 SL 5.6 mg is the first listed.
NCT03508700 reports 16 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT03508700 about?
NCT03508700 is a clinical study titled "A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD". Evaluate the long-term safety of TNX-102 SL 5.6 mg taken daily at bedtime over an additional 40 weeks in patients with PTSD who have participated in a double-blind lead-in study and completed an initial 12-week open-label extension study (TNX-CY-P303).
What is the current status of trial NCT03508700?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2018-04-19. Estimated completion is 2019-09-30.
What conditions does trial NCT03508700 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT03508700?
The interventions under investigation include: TNX-102 SL 5.6 mg (DRUG).
Who is sponsoring clinical trial NCT03508700?
This trial is sponsored by Tonix Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03508700 being conducted?
This trial has 16 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposing Low-Dose Clonidine for PTSD in Veterans
RECRUITING · Phase 3
-
Individual PE vs Couples' CBT for Combat-Related Posttraumatic Stress Disorder
COMPLETED · Phase 3
-
Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD
COMPLETED · Phase 3
-
Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder)
COMPLETED · Phase 3
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Treatments for Insomnia in Veterans With PTSD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.